The Cooper Companies, Inc. filings document a Nasdaq-listed medical device company with common stock trading under the symbol COO. Its regulatory disclosures include Form 8-K reports on quarterly results, board and officer changes, annual meeting voting results, and material definitive agreements, including amendments to term loan arrangements.
Proxy materials describe director elections, board committee matters, executive compensation, shareholder proposals, and governance practices. Together, the filings record operating and financial disclosures for CooperVision and CooperSurgical, capital structure information, debt arrangements, stockholder voting mechanics, and risk and governance topics relevant to the company’s contact lens, fertility, and women’s healthcare businesses.
Capital World Investors filed an amendment to a Schedule 13G/A reporting beneficial ownership of 7,834,830 shares of Cooper Companies, Inc. common stock, representing 4.0% of the 195,114,398 shares the filer believes to be outstanding. The filing states sole voting power for 7,775,389 shares and sole dispositive power for 7,834,830 shares. The filing is signed by Jae Won Chung of Capital Research and Management Company on 05/13/2026.
CooperCompanies is expanding its Board of Directors from nine to ten members and has appointed Paul Keel as an independent director, effective July 1, 2026. He will also join the Board’s Audit Committee on that date.
Keel is currently President and CEO of Envista Holdings Corporation and previously served as CEO of Smiths Group plc, following 16 years in leadership roles at 3M. He will receive director compensation consistent with other non-employee directors. The company highlights its global medical device focus through CooperVision and CooperSurgical, serving more than fifty million people annually in over 130 countries.
Cooper Cos Inc/The reports a 13G filing showing Vanguard Capital Management beneficially owns 14,664,697 shares of Common Stock, representing 7.51% of the class as of 03/31/2026. The filing states Vanguard has sole power to dispose of 14,664,697 shares and sole voting power for 1,945,868 shares. The disclosure attributes holdings to Vanguard Capital Management and named affiliates and is signed on 04/29/2026.
COOPER COMPANIES, INC. director Walter M. Rosebrough Jr reported routine equity compensation activity. On January 3, 2026, he received a grant of 832 Restricted Stock Units, each linked to one share of common stock and scheduled to vest on April 1, 2026.
On April 1, 2026, these 832 RSUs were exercised and converted into 832 shares of common stock, which he now holds directly. The filing shows an additional 10,000 shares of common stock held indirectly through the Walter M. Rosebrough Jr Revocable Trust, where he is sole trustee. The company notes the Form 4 was filed late due to an inadvertent administrative oversight.
The Cooper Companies, Inc. reported results of its 2026 Annual Meeting of Stockholders held on April 7, 2026. Stockholders elected all nine director nominees, ratified KPMG LLP as independent auditor for the fiscal year ending October 31, 2026, and approved executive compensation on an advisory basis.
Cooper Companies director Robert S. Weiss reported routine equity compensation activity. On April 1, 2026, he exercised 3,654 Restricted Stock Units, receiving the same number of common shares at $0.00 per share, bringing his direct common stock holdings to 292,599 shares.
On the same date, he was granted 3,779 new Restricted Stock Units, each tied to an equal number of common shares and subject to future vesting or forfeiture. He also reports 257,860 common shares held indirectly by the Robert and Marilyn Weiss Trust dated 5/17/06, for which he and his spouse serve as co‑trustees. No open‑market purchases or sales were reported.
Cooper Companies director Maria Rivas reported routine equity compensation changes. She exercised restricted stock units into 3,322 shares of common stock on April 1, 2026, and now holds 3,322 shares directly. She also received a new grant of 3,779 restricted stock units scheduled to vest on April 1, 2027. In addition, 11,141 common shares are held indirectly through The Maria Rivas Trust Dated June 24, 2013, where she serves as sole trustee.
Cooper Companies director Colleen Jay reported equity compensation activity involving restricted stock units and common shares. On April 1, 2026, 3,322 restricted stock units were exercised and converted into 3,322 shares of common stock. On the same date, Jay also received a new grant of 4,157 restricted stock units, which may vest or be forfeited and has no expiration date. Following these transactions, Jay directly owned 39,907 shares of common stock and held 4,157 restricted stock units.
Cooper Companies director Barbara Carbone reported routine equity compensation activity. On April 1, 2026, she exercised 3,050 Restricted Stock Units, converting them into 3,050 shares of Common Stock at a stated price of $0.00 per share, reflecting non-cash vesting rather than a market purchase.
On the same date, she also received a new grant of 3,779 Restricted Stock Units, each representing a right to acquire one share of Common Stock. The award has no expiration date; the units will either vest or be forfeited over time. Following these transactions, she directly holds 3,050 shares of Common Stock and 3,779 Restricted Stock Units.
Rosebrough Walter M Jr reported acquisition or exercise transactions in this Form 4 filing.
COOPER COMPANIES, INC. director Walter M. Rosebrough Jr received a grant of 3,779 Restricted Stock Units on April 1, 2026 as equity compensation. Each unit represents one share of common stock.
The RSUs are scheduled to vest on April 1, 2027 and have no expiration date; they will either vest or be forfeited. Following this award, he holds 3,779 RSUs directly, and there were no open-market purchases or sales in this filing.